Medifocus Inc. Announces Maxim Group as Financial Advisor and Investment Banker
Submitted by Medifocus Inc. on Wednesday, 07/24/2013
COLUMBIA, Md. and Toronto, ON- July 24, 2013 – Medifocus, Inc. (OTCQX: MDFZF and TSXV: MFS) announced today that it has enlisted the services of Maxim Group LLC, a leading investment banking, securities and investment management firm, to provide strategic corporate finance and investment banking services. Maxim will focus on assisting Medifocus in its strategies for maximizing shareholder value through its full scope of investment banking services.
Augustine Cheung, CEO of Medifocus, Inc., commented, “We are looking forward to utilizing the expertise of Maxim Group to assist our company as we move towards commercialization of our patented APA microwave focusing technology platform for the treatment of breast cancer and grow our sales from our Prolieve® Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH).” He continued, “Maxim is a major investment banking firm concentrated on advising small-cap and mid-sized organizations. We believe that, with Maxim’s support, we can strategically move forward to achieve continued sales growth and deliver enhanced shareholder value.”
Maxim representatives commented, “We are delighted to partner with Medifocus as it pursues its plan to establish a unique position within the cancer and BPH treatment markets. Our goal will be to provide assistance to Medifocus in the financial and value creation components of its corporate strategy through our full-service investment banking capabilities. Furthermore, we will also be supporting Medifocus in attaining its strategic initiatives and long-term objectives as it moves forward with the roll out of its proprietary, minimally-invasive focused heat thermotherapy systems.”
Medifocus develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). With the recent acquisition of Prolieve®, Medifocus now owns a revenue generating commercial BPH treatment product targeting the estimated $8 billion BPH drug therapy market and generating cash flow to support the development and commercialization of other catheter based or Adaptive Phased Array (APA) based focused heat systems for targeted thermotherapy of surface, subsurface and deep seated localized and regional cancers.
The Company owns two technology platforms with comprehensive US and international patent protection: 1: The Endo-thermotherapy Platform-from which Prolieve was developed can potentially used to treat cancers in prostate, rectal, cervical and esophageal, and 2: The Adaptive Phased Array (APA) Microwave Focusing Platform-invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company’s APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, is currently in pivotal Phase-III clinical trials.
www.medifocusinc.com, www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.
About Maxim Group LLC:
Maxim Group LLC is a full-service investment banking firm headquartered in New York. Maxim Group provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales and trading as well as equity research. The investment banking group focuses on middle market and emerging growth companies within the shipping, energy, healthcare, technology, retail, and business and financial services sectors. The institutional coverage of Maxim Group spans North and South America, Europe and Asia. Maxim Group LLC is registered as a broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
Safe Harbor Statement
This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of CCTI, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Company John Mon, COO, Medifocus, Inc. Tel: 410-290-5734 firstname.lastname@example.org